Feature | Patients | |||||
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | |
Diagnostic indication | RA | RA | RA | PsA | RA | RA |
Age at onset, yrs | 39 | 49 | 54 | 50 | 33 | 34 |
RF | − | + | + | − | − | + |
Anti-CCP | − | + | − | − | − | − |
Bony erosions | + | + | − | + | − | − |
TNF blockers | ||||||
Infliximab | 2002* | |||||
Etanercept | 2001* | 1998* | 2003* | 2002* | 2008* | 2001* |
Adalimumab | 2005* | |||||
ANA before treatment | Speckled 1:1250 | Unknown | Homogenous 1:1250 | Unknown | Negative | Homogenous 1:1250 |
ANA after treatment | Speckled 1:6250 | Homogenous 1:6250 | Homogenous 1:6250 | Nucleolar and homogenous 1:6250 | Homogenous 1:1250 | Homogenous 1:1250 |
Onset of SLE after initiation of TNF blocker | 6 mo | 6 yrs | 2–4 mo | 3 yrs | 1 mo | 7 yrs |
↵* Year TNF inhibitor was started. Anti-CCP: citric citrullinated peptide antibodies.